Summit Therapeutics (SMMT) stock, a potential rival for Merck (MRK) traded lower as Leerink Partners started its coverage with a Sell-equivalent rating. Read more here.

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...

Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 10:00 AM ETCompany ParticipantsAdam Lenkowsky ...

VEGF and PD-1 targeting drugs from the likes of ... in yet another signal of China's role as an emerging source of biopharma R&D innovation. A Bloomberg report indicated that the upfront payment ...

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also ...

When it comes to the U.S. biopharma market, pricing seems to be the driving focus of most congressional conversations – and ...

Since the approval of Luxturna, there has been a wave of gene therapies advancing in clinical trials to treat genetic vision ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

This adds to BioDlink's portfolio of international GMP approvals, following recent certifications in Brazil, Indonesia, Egypt ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn ...

People using the popular weight loss injections including Ozempic and Wegovy could be more at risk of osteoporosis and bone ...